Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06215261 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD
A Phase 2 study, sponsored by Transcend Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT06215261 is a Phase 2 study that has completed, run by Transcend Therapeutics. The registered enrollment target is 62 participants.
The verdict
NCT06215261, a Phase 2 study, has completed, sponsored by Transcend Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This study is evaluating the safety and efficacy of methylone in adults with PTSD. The study is conducted in two parts. * Part A is open-label and will enroll up to 15 participants with PTSD * Part B is randomized (1:1:1), single-blind and will enroll up to 45 participants with PTSD Eligible participants will enter a 3-week Treatment Period (Part A) or 4-week Treatment Period (Part B) where they will receive methylone once weekly. Following the Treatment Period, participants will enter a 6-week Follow-up Period (Part A) or 8-week Follow-up Period (Part B).
Interventions
- DRUG Methylone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-04-04 |
| Est. Completion | 2025-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06215261
The ClinicalTrials.gov registry entry for NCT06215261 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Transcend Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Methylone is the first listed.
NCT06215261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06215261 about?
NCT06215261 is a clinical study titled "An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD". This study is evaluating the safety and efficacy of methylone in adults with PTSD. The study is conducted in two parts. * Part A is open-label and will enroll up to 15 participants with PTSD * Part B is randomized (1:1:1), single-blind and will enroll up to 45 participants with PTSD Eligible parti...
What is the current status of trial NCT06215261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2024-04-04. Estimated completion is 2025-09-23.
What interventions are being tested in trial NCT06215261?
The interventions under investigation include: Methylone (DRUG).
Who is sponsoring clinical trial NCT06215261?
This trial is sponsored by Transcend Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.